The median percentage of PD-L1+ monocytes was much higher in patients who experienced disease progression than that in patients without progression (81.8 vs. 23.4% in blood, P < 0.001; 39.1 vs. 6.7% in tumor, P < 0.001). This evidence concerns the gene CD274 and neoplasm.